Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients

Journal of Neurology

Volumn 253, Issue 2, 2006, Pages 231-236

  Ruggieri, Maddalena ^a   Avolio, Carlo ^b   Scacco, Salvatore ^a   Pica, Carmela ^a   Lia, Anna ^a   Zimatore, Giovanni B ^a   Papa, Sergio ^a   Livrea, Paolo ^a   Trojano, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Apoptosis; Glatiramer acetate; Multiple sclerosis

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; GLATIRAMER; PROTEIN BAX; PROTEIN BCL 2;

ADULT; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MITOCHONDRION; MULTIPLE SCLEROSIS; OXYGEN CONSUMPTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIROMETRY; T LYMPHOCYTE; WESTERN BLOTTING;

ADULT; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; CASE-CONTROL STUDIES; CYTOCHROMES C; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OXYGEN CONSUMPTION; PEPTIDES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; ROTENONE; STATISTICS, NONPARAMETRIC; TIME FACTORS; UNCOUPLING AGENTS;

EID: 32844471257     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-005-0965-y     Document Type: Article

References (27)

1. Aktas O, Ari N, Rieks M, Hoffmann V, Schimrigk S, Przuntek H, Pohlau D (2001) Multiple Sclerosis: modulation of apoptosis susceptibility by glatiramer acetate. Acta Neurol Scand 104:266-270
2. Comi G, Filippi M, Wolinsky JS and the European/Canadian Glatiramer Acetate Study Group (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49:290-297
3. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G and the European/Canadian Glatiramer Acetate Study Group (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57:731-733
4. Gniadek P, Aktas O, Wandinger KP, Strobl JB, Wengert O, Weber A, von Wussow P, Obert HJ, Zipp F (2003) Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. J Neuroimmunol 137:187-196
5. Green DR, Reed JC (1998). Mitochondria and apoptosis. Science 281:1309-1312
6. Kaser A, Deisenhammer F, Berger T, Tilg H (1999) Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients. Lancet 353:1413-1414
7. Krammer PH (2000) CD95's deadly mission in the immune system. Nature 407:789-795
8. Lenardo MJ, Chan FK, Hornung F, McFarland HF, Siegel R, Wang J, Zheng L (1999) Mature T lymphocyte apoptosis - Immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17:221-253
9. Martinou J-C, Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cel Biol 2:63-67
10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
11. Pender MP (1998) Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 351:978-981
12. Rathmell JC, Thompson CB (1999) The central effectors of cell death in the immune system. Annu Rev Immunol 17:781-828
13. Rieks M, Hoffmann V, Aktas O, Juschka M, Spitzer I, Brune N, Schimrigk S, Przuntek H, Pohlau D (2003) Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of Multiple Sclerosis with Glatiramer Acetate. Eur Neurol 50:200-206
14. Sabelko DKA, Russell JH, Cross AH (1999) Role of Fas - FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J Neuroimmunol 100:42-52
15. Segal BM, Cross AH (2000) Fas(t) track to apoptosis in MS-TNF receptors may suppress or potentiate CNS demyelination. Neurology 55:906-907
16. Sharief MK (2000) Increased cellular expression of the caspase inhibitor FLIP in intrathecal lymphocytes from patients with multiple sclerosis. J Neuroimmunol 111:203-209
17. Sharief MK, Semra YK (2001) Heightened expression of surviving in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 119:358-364
18. Sharief MK, Semra YK (2001) Upregulation of the inhibitor of apoptosis proteins in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 119:350-357
19. Sharief MK, Semra YK, Seidi OA, Zoukos Y (2001) Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 120:199-207
20. Sharief MK, Douglas M, Noori MA, Semra YK (2002) The expression of pro- and anti-apoptosis Bcl-2 family proteins in lymphocytes from patients with multiple sclerosis. J Neuroimmunol 125:155-162
21. Sharief MK, Noori MA, Zoukos Y (2002) Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-β therapy. J Neuroimmunol 129:224-231
22. Sharief MK, Matthews H, Noori MA (2003) Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis. J Neuroimmunol 134:158-165
23. Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jemberg-Wiklund H (1998) Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon-alpha in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 92:2914-2923
24. Van Parijs L, Abbas AK (1998) Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243-248
25. Zipp F (2000) Apoptosis in multiple sclerosis. Cell Tissue Res 301:163-171
26. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M (1998) Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 86:151-154
27. Zipp F, Krammer PH, Weller M (1999) Immune (dys)regulation in multiple sclerosis: role of the CD95/CD95 ligand system. Immunol Today 20:550-554